摘要：
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four yearsand older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). Mylan obtained approval to market its generic inhaler in three strengths: fluticasone propionate 100 mcg/ salmeterol 50 mcg, fluticasone propionate 250 mcg/ salmeterol 50 mcg and fluticasone propionate 500 mcg/ salmeterol 50 mcg
Supporting:
http://www.fda.gov. Information from US FDA[J]. 中国药学(英文版), 2019, 28(2): 143-144.
http://www.fda.gov. Information from US FDA[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(2): 143-144.
>
>